U.S. stock market intraday update: Aptorum Group rises 118.17%

U.S. Stock Market Midday Update Aptorum surged 118.17%, with increased trading volume. Based on recent important news: On August 21, DiamiR Biosciences and Aptorum announced the approval of CLEP testing by the New York State Department of Health, promoting innovative diagnostic testing, leading to a 118.17% increase in stock price. On August 19, the A-share market experienced a surge, driven by policies and industrial upgrades, with the machinery and electronics industry leading the gains. On August 20, the Hong Kong Stock Exchange announced its interim results, with shareholders' profit attributable rising 39% year-on-year, and market trading volume hitting a semi-annual high. Stocks with High Trading Volume in the Industry Tharimmune rose 42.55%, with increased trading volume. Based on recent important news: On August 20, Tharimmune released an initial beneficial ownership statement, listing Gary S. Stetz as the beneficial owner, which was positively received by the market, resulting in a significant 42.55% increase in stock price. On August 21, Tharimmune released another initial beneficial ownership statement, listing Vincent S. LoPriore as the beneficial owner, further driving up the stock price. On August 20, Tharimmune published news through ACCESS Newswire, boosting market confidence in the company's future development. Protagenic Therapeutics rose 65.79%, with a trading volume of $109 million. Based on recent important news: On August 21, Protagenic Therapeutics announced a collaboration with Arrow to promote company development, leading to a significant 65.79% increase in stock price. On August 20, Stone Technology's semi-annual report showed a 67.28% increase in R&D investment, enhancing market confidence in the high-tech sector. On August 18, Soligenix received FDA orphan drug designation, with its stock price rising 47.5%, driving up related biotech stocks. AbbVie rose 0.14%, with increased trading volume. Based on recent important news: On August 21, AbbVie announced positive results from its Phase 3 UP-AA study, showing significant effects of upadacitinib in treating patients with severe alopecia areata, driving up the stock price. On August 19, AbbVie completed its acquisition of Capstan Therapeutics, a deal valued at up to $2.1 billion, strengthening its position in the autoimmune disease field. On August 18, AbbVie's dividend yield was 3.2%, significantly higher than the average level of the S&P 500, attracting long-term investors Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen fell 0.38%, with increased trading volume. Based on recent key news: On August 20, MarketBeat pointed out that Amgen was not included in the list of five stocks recommended by top analysts, leading to a decline in investor confidence and a drop in stock price. On August 18, MarketBeat reiterated that Amgen was only rated as a hold, with better investment options available, further dampening market sentiment. On August 20, the news of Hansoh Pharmaceutical's share placement attracted market attention to pharmaceutical stocks, but Amgen failed to benefit and was instead negatively impacted